Literature DB >> 2801843

Absorption of oral progesterone is influenced by vehicle and particle size.

J T Hargrove1, W S Maxson, A C Wentz.   

Abstract

The oral route of progesterone administration has long been considered impractical because of poor absorption and short biologic half-life. Recent reports suggest that micronization of progesterone enhances absorption and increases serum and tissue levels of progesterone. This study checks serum progesterone levels before and 0.5, 1, 2, 3, 4, and 6 hours after oral administration of 200 mg of progesterone in seven subjects. Progesterone was plain milled, micronized, plain milled in oil, micronized in oil, or micronized in enteric-coated capsules. All patients exhibited a significant increase in serum progesterone levels after oral progesterone administration. Mean peak progesterone levels (30.3 +/- 7.0 ng/ml) (p less than 0.005) were achieved with micronized progesterone in oil at 2.0 +/- 0.3 (p less than 0.05) hours after administration. Four types of oral progesterone had equivalent mean peak elevations and mean times to peak: plain milled, 9.6 +/- 2.5 ng/ml at 4.0 +/- 0.5 hours; micronized 13.2 +/- 2.4 ng/ml at 3.2 +/- 0.4 hours; plain milled in oil, 11.3 +/- 3.0 ng/ml at 4.0 +/- 0.5 hours; and micronized in enteric-coated capsules, 11.2 +/- 3.0 ng/ml at 4.1 +/- 0.7 hours. Contrary to traditional teaching, these data show that significant serum progesterone levels can be achieved by oral administration. Absorption can be significantly improved by the physical characteristics of the progesterone and the vehicle used with oral administration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2801843     DOI: 10.1016/0002-9378(89)90759-x

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

1.  A placebo-controlled study of effects of oral progesterone on performance and mood.

Authors:  E W Freeman; L Weinstock; K Rickels; S J Sondheimer; C Coutifaris
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

2.  Hormone levels in preterm and donor human milk before and after Holder pasteurization.

Authors:  Réka A Vass; Edward F Bell; Tarah T Colaizy; Mendi L Schmelzel; Karen J Johnson; Jacky R Walker; Tibor Ertl; Robert D Roghair
Journal:  Pediatr Res       Date:  2020-01-30       Impact factor: 3.756

Review 3.  Deciphering the divergent roles of progestogens in breast cancer.

Authors:  Jason S Carroll; Theresa E Hickey; Gerard A Tarulli; Michael Williams; Wayne D Tilley
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

Review 4.  Progesterone for premenstrual syndrome.

Authors:  Olive Ford; Anne Lethaby; Helen Roberts; Ben Willem J Mol
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

5.  Clinical studies with oral lipid based formulations of poorly soluble compounds.

Authors:  Dimitrios G Fatouros; Ditte M Karpf; Flemming S Nielsen; Anette Mullertz
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

6.  Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study.

Authors:  Chetan Detroja; Sandip Chavhan; Krutika Sawant
Journal:  Sci Pharm       Date:  2011-07-05

7.  Solubility Improvement of Progesterone from Solid Dispersions Prepared by Solvent Evaporation and Co-milling.

Authors:  Xing Chen; Ioannis Partheniadis; Ioannis Nikolakakis; Hisham Al-Obaidi
Journal:  Polymers (Basel)       Date:  2020-04-07       Impact factor: 4.329

Review 8.  A review of conventional and sustained-release formulations of oral natural micronized progesterone in obstetric indications.

Authors:  Girija Narendrakumar Wagh; K M Kundavi Shankar; Sumitra Bachani
Journal:  Drugs Context       Date:  2021-10-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.